Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer

Kenji Tsuchihashi, Mamoru Ito, Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Akitaka Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Kenji Katsumata, Toshiaki Ishikawa, Tomomi Kashiwada, Eiji Oki, Yoshito Komatsu & 8 others Hiroyuki Okuyama, Daisuke Sakai, Hideki Ueno, Takao Tamura, Kimihiro Yamashita, Junji Kishimoto, Yasuhiro Shimada, Eishi Baba

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

The survival and safety of patients with metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib as later-line chemotherapy were retrospectively examined according to the modified Glasgow Prognostic Score (mGPS). Overall and progression-free survival were strongly correlated with mGPS in all patients. The frequency of adverse events was generally similar in each mGPS group. Background: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated. Patients and Methods: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. Results: The median overall survival (OS) of patients with mGPS 0, 1, and 2 was 10.0 months (95% confidence interval [CI], 9.2-11.6 months), 6.5 months (95% CI, 5.3-7.1 months), and 3.9 months (95% CI, 3.3-4.9 months), respectively. The median progression-free survival (PFS) with mGPS 0, 1, and 2 was 2.5 months (95% CI, 2.1-3.0 months), 2.0 months (95% CI, 1.9-2.3 months), and 1.7 months (95% CI, 1.4-1.9 months), respectively. There were significant differences by mGPS in both OS and PFS (all P <.001). No significant differences in OS and PFS were observed between the patient groups treated with TFTD and regorafenib in each mGPS group. In patients aged ≥ 65 years with mGPS 2, the OS and PFS were worse with regorafenib than with TFTD (OS: hazard ratio, 1.45; 95% CI, 0.93-2.25; P =.097; PFS: hazard ratio, 1.57, 95% CI, 1.01-2.44; P =.047), but there were no consistent trends observed as mGPS increased. The frequency of grade 3 and more adverse events was generally similar in each mGPS group. The multivariate analyses showed that mGPS was the strongest predictive factor for OS. Conclusions: The mGPS before later-line chemotherapy is strongly correlated with survival in patients with mCRC.

元の言語英語
ページ(範囲)e687-e697
ジャーナルClinical Colorectal Cancer
17
発行部数4
DOI
出版物ステータス出版済み - 12 1 2018

Fingerprint

Colorectal Neoplasms
Drug Therapy
Confidence Intervals
Disease-Free Survival
Survival
Trifluridine
Patient Safety
Nutritional Status
Serum Albumin
C-Reactive Protein
Multicenter Studies
Observational Studies
Multivariate Analysis
regorafenib
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

これを引用

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. / Tsuchihashi, Kenji; Ito, Mamoru; Moriwaki, Toshikazu; Fukuoka, Shota; Taniguchi, Hiroya; Takashima, Atsuo; Kumekawa, Yosuke; Kajiwara, Takeshi; Yamazaki, Kentaro; Esaki, Taito; Makiyama, Akitaka; Denda, Tadamichi; Satake, Hironaga; Suto, Takeshi; Sugimoto, Naotoshi; Katsumata, Kenji; Ishikawa, Toshiaki; Kashiwada, Tomomi; Oki, Eiji; Komatsu, Yoshito; Okuyama, Hiroyuki; Sakai, Daisuke; Ueno, Hideki; Tamura, Takao; Yamashita, Kimihiro; Kishimoto, Junji; Shimada, Yasuhiro; Baba, Eishi.

:: Clinical Colorectal Cancer, 巻 17, 番号 4, 01.12.2018, p. e687-e697.

研究成果: ジャーナルへの寄稿記事

Tsuchihashi, K, Ito, M, Moriwaki, T, Fukuoka, S, Taniguchi, H, Takashima, A, Kumekawa, Y, Kajiwara, T, Yamazaki, K, Esaki, T, Makiyama, A, Denda, T, Satake, H, Suto, T, Sugimoto, N, Katsumata, K, Ishikawa, T, Kashiwada, T, Oki, E, Komatsu, Y, Okuyama, H, Sakai, D, Ueno, H, Tamura, T, Yamashita, K, Kishimoto, J, Shimada, Y & Baba, E 2018, 'Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer' Clinical Colorectal Cancer, 巻. 17, 番号 4, pp. e687-e697. https://doi.org/10.1016/j.clcc.2018.07.004
Tsuchihashi, Kenji ; Ito, Mamoru ; Moriwaki, Toshikazu ; Fukuoka, Shota ; Taniguchi, Hiroya ; Takashima, Atsuo ; Kumekawa, Yosuke ; Kajiwara, Takeshi ; Yamazaki, Kentaro ; Esaki, Taito ; Makiyama, Akitaka ; Denda, Tadamichi ; Satake, Hironaga ; Suto, Takeshi ; Sugimoto, Naotoshi ; Katsumata, Kenji ; Ishikawa, Toshiaki ; Kashiwada, Tomomi ; Oki, Eiji ; Komatsu, Yoshito ; Okuyama, Hiroyuki ; Sakai, Daisuke ; Ueno, Hideki ; Tamura, Takao ; Yamashita, Kimihiro ; Kishimoto, Junji ; Shimada, Yasuhiro ; Baba, Eishi. / Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. :: Clinical Colorectal Cancer. 2018 ; 巻 17, 番号 4. pp. e687-e697.
@article{d4d9fd6041e643c2b0ec8fe1a6074800,
title = "Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer",
abstract = "The survival and safety of patients with metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib as later-line chemotherapy were retrospectively examined according to the modified Glasgow Prognostic Score (mGPS). Overall and progression-free survival were strongly correlated with mGPS in all patients. The frequency of adverse events was generally similar in each mGPS group. Background: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated. Patients and Methods: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. Results: The median overall survival (OS) of patients with mGPS 0, 1, and 2 was 10.0 months (95{\%} confidence interval [CI], 9.2-11.6 months), 6.5 months (95{\%} CI, 5.3-7.1 months), and 3.9 months (95{\%} CI, 3.3-4.9 months), respectively. The median progression-free survival (PFS) with mGPS 0, 1, and 2 was 2.5 months (95{\%} CI, 2.1-3.0 months), 2.0 months (95{\%} CI, 1.9-2.3 months), and 1.7 months (95{\%} CI, 1.4-1.9 months), respectively. There were significant differences by mGPS in both OS and PFS (all P <.001). No significant differences in OS and PFS were observed between the patient groups treated with TFTD and regorafenib in each mGPS group. In patients aged ≥ 65 years with mGPS 2, the OS and PFS were worse with regorafenib than with TFTD (OS: hazard ratio, 1.45; 95{\%} CI, 0.93-2.25; P =.097; PFS: hazard ratio, 1.57, 95{\%} CI, 1.01-2.44; P =.047), but there were no consistent trends observed as mGPS increased. The frequency of grade 3 and more adverse events was generally similar in each mGPS group. The multivariate analyses showed that mGPS was the strongest predictive factor for OS. Conclusions: The mGPS before later-line chemotherapy is strongly correlated with survival in patients with mCRC.",
author = "Kenji Tsuchihashi and Mamoru Ito and Toshikazu Moriwaki and Shota Fukuoka and Hiroya Taniguchi and Atsuo Takashima and Yosuke Kumekawa and Takeshi Kajiwara and Kentaro Yamazaki and Taito Esaki and Akitaka Makiyama and Tadamichi Denda and Hironaga Satake and Takeshi Suto and Naotoshi Sugimoto and Kenji Katsumata and Toshiaki Ishikawa and Tomomi Kashiwada and Eiji Oki and Yoshito Komatsu and Hiroyuki Okuyama and Daisuke Sakai and Hideki Ueno and Takao Tamura and Kimihiro Yamashita and Junji Kishimoto and Yasuhiro Shimada and Eishi Baba",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.clcc.2018.07.004",
language = "English",
volume = "17",
pages = "e687--e697",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer

AU - Tsuchihashi, Kenji

AU - Ito, Mamoru

AU - Moriwaki, Toshikazu

AU - Fukuoka, Shota

AU - Taniguchi, Hiroya

AU - Takashima, Atsuo

AU - Kumekawa, Yosuke

AU - Kajiwara, Takeshi

AU - Yamazaki, Kentaro

AU - Esaki, Taito

AU - Makiyama, Akitaka

AU - Denda, Tadamichi

AU - Satake, Hironaga

AU - Suto, Takeshi

AU - Sugimoto, Naotoshi

AU - Katsumata, Kenji

AU - Ishikawa, Toshiaki

AU - Kashiwada, Tomomi

AU - Oki, Eiji

AU - Komatsu, Yoshito

AU - Okuyama, Hiroyuki

AU - Sakai, Daisuke

AU - Ueno, Hideki

AU - Tamura, Takao

AU - Yamashita, Kimihiro

AU - Kishimoto, Junji

AU - Shimada, Yasuhiro

AU - Baba, Eishi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The survival and safety of patients with metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib as later-line chemotherapy were retrospectively examined according to the modified Glasgow Prognostic Score (mGPS). Overall and progression-free survival were strongly correlated with mGPS in all patients. The frequency of adverse events was generally similar in each mGPS group. Background: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated. Patients and Methods: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. Results: The median overall survival (OS) of patients with mGPS 0, 1, and 2 was 10.0 months (95% confidence interval [CI], 9.2-11.6 months), 6.5 months (95% CI, 5.3-7.1 months), and 3.9 months (95% CI, 3.3-4.9 months), respectively. The median progression-free survival (PFS) with mGPS 0, 1, and 2 was 2.5 months (95% CI, 2.1-3.0 months), 2.0 months (95% CI, 1.9-2.3 months), and 1.7 months (95% CI, 1.4-1.9 months), respectively. There were significant differences by mGPS in both OS and PFS (all P <.001). No significant differences in OS and PFS were observed between the patient groups treated with TFTD and regorafenib in each mGPS group. In patients aged ≥ 65 years with mGPS 2, the OS and PFS were worse with regorafenib than with TFTD (OS: hazard ratio, 1.45; 95% CI, 0.93-2.25; P =.097; PFS: hazard ratio, 1.57, 95% CI, 1.01-2.44; P =.047), but there were no consistent trends observed as mGPS increased. The frequency of grade 3 and more adverse events was generally similar in each mGPS group. The multivariate analyses showed that mGPS was the strongest predictive factor for OS. Conclusions: The mGPS before later-line chemotherapy is strongly correlated with survival in patients with mCRC.

AB - The survival and safety of patients with metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib as later-line chemotherapy were retrospectively examined according to the modified Glasgow Prognostic Score (mGPS). Overall and progression-free survival were strongly correlated with mGPS in all patients. The frequency of adverse events was generally similar in each mGPS group. Background: Assessment of patient factors is essential for selecting later-line chemotherapy in patients with metastatic colorectal cancer (mCRC). The efficacy, prognosis, and safety of each treatment regimen according to nutritional and inflammatory status still remain to be elucidated. Patients and Methods: A total of 550 patients with mCRC who were registered in the REGOTAS study (Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study, UMIN 000020416) and treated with trifluridine/tipiracil (TFTD) or regorafenib as a later-line therapy were retrospectively stratified according to the modified Glasgow Prognostic Score (mGPS), which divided patients into mGPS 0 to 2 by serum albumin and C-reactive protein, and compared. Results: The median overall survival (OS) of patients with mGPS 0, 1, and 2 was 10.0 months (95% confidence interval [CI], 9.2-11.6 months), 6.5 months (95% CI, 5.3-7.1 months), and 3.9 months (95% CI, 3.3-4.9 months), respectively. The median progression-free survival (PFS) with mGPS 0, 1, and 2 was 2.5 months (95% CI, 2.1-3.0 months), 2.0 months (95% CI, 1.9-2.3 months), and 1.7 months (95% CI, 1.4-1.9 months), respectively. There were significant differences by mGPS in both OS and PFS (all P <.001). No significant differences in OS and PFS were observed between the patient groups treated with TFTD and regorafenib in each mGPS group. In patients aged ≥ 65 years with mGPS 2, the OS and PFS were worse with regorafenib than with TFTD (OS: hazard ratio, 1.45; 95% CI, 0.93-2.25; P =.097; PFS: hazard ratio, 1.57, 95% CI, 1.01-2.44; P =.047), but there were no consistent trends observed as mGPS increased. The frequency of grade 3 and more adverse events was generally similar in each mGPS group. The multivariate analyses showed that mGPS was the strongest predictive factor for OS. Conclusions: The mGPS before later-line chemotherapy is strongly correlated with survival in patients with mCRC.

UR - http://www.scopus.com/inward/record.url?scp=85052093643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052093643&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2018.07.004

DO - 10.1016/j.clcc.2018.07.004

M3 - Article

VL - 17

SP - e687-e697

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 4

ER -